Skip to main content
. 2018 Jul 26;103(9):1422–1432. doi: 10.3324/haematol.2018.191288

Table 3.

Incidence of cardiovascular events in patients with newly diagnosed multiple myeloma treated with carfilzomib in phase 1, 2 and 3 studies.

graphic file with name 1031422.tab3.jpg